How does RECm's PE Ratio compare to its peers?

RECm is good value based on its Price-To-Earnings Ratio (25.3x) compared to the peer average (26.2x).

How does RECm's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

RECm is expensive based on its Price-To-Earnings Ratio (25.3x) compared to the European Pharmaceuticals industry average (20.3x).

What is RECm's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate RECm's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of RECm when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

RECm (€52.03) is trading below our estimate of [[fair value]] (€55.05)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is less than 20% higher than the current share price.

Recordati Industria Chimica e Farmaceutica (BATS-CHIXE:RECm) - Stock Price, News & Analysis

RECm Stock Overview

Engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. More details

RECm fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	6/6
Financial Health	4/6
Dividends	5/6

Rewards

Trading at 5.5% below our estimate of its fair value

Earnings are forecast to grow 11.52% per year

Earnings grew by 12.7% over the past year

Pays a reliable dividend of 2.3%

Risk Analysis

Shares are highly illiquid

Has a high level of debt

Recordati Industria Chimica e Farmaceutica S.p.A. Competitors

Hikma Pharmaceuticals

LSE:HIK

UK£4.4b

GSK

LSE:GSK

UK£54.9b

AstraZeneca

LSE:AZN

UK£162.4b

Animalcare Group

AIM:ANCR

UK£148.5m

Price History & Performance

Summary of all time highs, changes and price drops for Recordati Industria Chimica e Farmaceutica
Historical stock prices
Current Share Price	€52.03
52 Week High	€54.35
52 Week Low	€46.10
Beta	0.40
11 Month Change	-3.39%
3 Month Change	0.77%
1 Year Change	n/a
33 Year Change	-8.57%
5 Year Change	43.44%
Change since IPO	883.46%

Recent updates

Shareholder Returns

	RECm	GB Pharmaceuticals	GB Market
7D	0%	5.0%	2.2%
1Y	n/a	2.5%	8.8%

Return vs Industry: Insufficient data to determine how RECm performed against the UK Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how RECm performed against the UK Market.

Price Volatility

Is RECm's price volatile compared to industry and market?
RECm volatility
RECm Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: RECm's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine RECm's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1926	4,455	Rob Koremans	www.recordati.com

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing’s syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.

Recordati Industria Chimica e Farmaceutica S.p.A. Fundamentals Summary

How do Recordati Industria Chimica e Farmaceutica's earnings and revenue compare to its market cap?
RECm fundamental statistics
Market cap	€10.68b
Earnings (TTM)	€423.12m
Revenue (TTM)	€2.27b

25.3x

P/E Ratio

4.7x

P/S Ratio

Is RECm overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RECm income statement (TTM)
Revenue	€2.27b
Cost of Revenue	€666.44m
Gross Profit	€1.60b
Other Expenses	€1.18b
Earnings	€423.12m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	2.07
Gross Margin	70.63%
Net Profit Margin	18.65%
Debt/Equity Ratio	81.6%

How did RECm perform over the long term?

See historical performance and comparison

Dividends

2.3%

Current Dividend Yield

60%

Payout Ratio

RECm Stock Overview

Rewards

Risk Analysis

Recordati Industria Chimica e Farmaceutica S.p.A. Competitors

LSE:HIK

UK£4.4b

LSE:GSK

UK£54.9b

LSE:AZN

UK£162.4b

AIM:ANCR

UK£148.5m

Price History & Performance

Recent News & Updates

CVC Reportedly Taps Advisors to Study Options for Italy's Recordati

CVC Capital Reportedly Explores Options for its Controlling Stake in Recordati

Recordati Industria Chimica e Farmaceutica S.p.A., Annual General Meeting, Apr 22, 2024

Recordati Industria Chimica e Farmaceutica S.p.A. to Report Fiscal Year 2023 Results on Feb 22, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

CVC Reportedly Taps Advisors to Study Options for Italy's Recordati

CVC Capital Reportedly Explores Options for its Controlling Stake in Recordati

Recordati Industria Chimica e Farmaceutica S.p.A., Annual General Meeting, Apr 22, 2024

Recordati Industria Chimica e Farmaceutica S.p.A. to Report Fiscal Year 2023 Results on Feb 22, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Investor sentiment improves as stock rises 16%

Less than half of directors are independent

Full year 2022 earnings released

Recordati Industria Chimica e Farmaceutica S.p.A. to Report First Half, 2023 Results on Jul 28, 2023

Upcoming dividend of €0.55 per share

Second quarter 2022 earnings released: EPS: €0.27 (vs €0.57 in 2Q 2021)

Upcoming dividend of €0.57 per share

First quarter 2022 earnings released: EPS: €0.47 (vs €0.44 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Now 22% undervalued after recent price drop

Less than half of directors are independent

Upcoming dividend of €0.53 per share

Third quarter 2021 earnings released: EPS €0.43 (vs €0.38 in 3Q 2020)

Less than half of directors are independent

Less than half of directors are independent

Second quarter 2021 earnings released

Less than half of directors are independent

Upcoming dividend of €0.55 per share

First quarter 2021 earnings released: EPS €0.44 (vs €0.54 in 1Q 2020)

Full year 2020 earnings released: EPS €1.73 (vs €1.80 in FY 2019)

Full year 2020 earnings released

Revenue misses expectations

New 90-day low: €41.91

New 90-day low: €42.01

Recordati Announces the European Medicines Agency Accepts Marketing Authorization Application Submission by ARS Pharmaceuticals for review of ARS-1

ARS Pharmaceuticals, Inc. Announces Licensing Agreement with Recordati for Commercialization of Neffy

ARS Pharmaceuticals, Inc. and Recordati Announce Exclusive License for the Rights in Europe and Additional Countries for Neffy (Ars-1; Epinephrine Nasal Spray)

Shareholder Returns

Price Volatility

About the Company

Recordati Industria Chimica e Farmaceutica S.p.A. Fundamentals Summary

25.3x

4.7x

Earnings & Revenue

Dividends

2.3%

60%